<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903886</url>
  </required_header>
  <id_info>
    <org_study_id>BMREA ( 29BRC20.0019)</org_study_id>
    <nct_id>NCT04903886</nct_id>
  </id_info>
  <brief_title>Intensive Care Unit Acquired Infections in Patients Colonized With Extended Spectrum Enterobacteriaceae</brief_title>
  <acronym>BMREA</acronym>
  <official_title>Epidemiology of ICU-acquired Infections in Patients With Fecal Carriage of Extended Spectrum Betalactamase Enterobacteriaceae (ESBL-E)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worldwide emergence of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E)&#xD;
      had become a major problem in ICU, with at least 10% of incidence at the admission in Europe.&#xD;
      A systematic rectal swab is used in 70% of French ICU to detect intestinal ESBL-E carriage&#xD;
      The relationship between intestinal carriage and ICU-acquired infection is not perfectly&#xD;
      known. The investigators conducted a five years study monocentric retrospective observational&#xD;
      cohort in patients with presence of extended-spectrum β-lactamase-producing&#xD;
      Enterobacteriaceae in systematic rectal swabs to investigate which type of infections and&#xD;
      which bacteria are involved.&#xD;
&#xD;
      The investigators also collect data about antibiotherapy used to treat these infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intestinal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E)&#xD;
      had become a major problem in general population, morover in intensive care units. Systematic&#xD;
      rectal swab for screening is done in 70% of French ICU in routine. Some studies had show a&#xD;
      good negative predictive value of this test for ICU-acquired infection (for example&#xD;
      ventilator-associated pneumoniae), but a poor predictive positive value. The precise&#xD;
      relationship between intestinal carriage and ICU-acquired infection is not perfectly known.&#xD;
&#xD;
      Probabilist antibiotherapy with carbapenem for ESBL-E suspected infection are currently&#xD;
      recommanded by national and european Guidelines, particulary in case of shock or&#xD;
      immunodepression.&#xD;
&#xD;
      A ESBL-E systematic screening-guided strategy for probabilist antibiotherapy could be&#xD;
      interesting, and could lead to a carbapenem or a carbapenem-sparing focused antibiotherapy.&#xD;
&#xD;
      The investigators conducted a monocentric retrospective observational cohort study in&#xD;
      patients with presence of extended-spectrum β-lactamase-producing Enterobacteriaceae in&#xD;
      systematic rectal swabs to investigate the number of ESBL-E related infections, the site of&#xD;
      these infections and which species of bacteriae are involved. They also investigate which was&#xD;
      the antibiotherapy administered, and investigate what factors lead clinicians to treat the&#xD;
      infection with carbapenem antibiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of ESBL-E related infection in ICU-aquired infection</measure>
    <time_frame>28 days</time_frame>
    <description>proportion of ESBL-E related infection in ICU-aquired infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>use of carbapenem antibiotherapy</measure>
    <time_frame>28 days</time_frame>
    <description>use of carbapenem antibiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of ICU-stay</measure>
    <time_frame>28 days</time_frame>
    <description>length of ICU-stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital-stay</measure>
    <time_frame>28 days</time_frame>
    <description>length of hospital-stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate in ICU</measure>
    <time_frame>28 days</time_frame>
    <description>death in ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality in hospital</measure>
    <time_frame>28 days</time_frame>
    <description>death in hospital</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <condition>Bacteremia</condition>
  <condition>Abdominal Infection</condition>
  <condition>Enterobacteriaceae Infections</condition>
  <arm_group>
    <arm_group_label>All patient colonized with ESBL-E in Brest Intensive Care unit</arm_group_label>
    <description>All patient colonized with ESBL-E in Brest Intensive Care unit, in a 5 years period (2015-2019)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>observational</intervention_name>
    <description>observational</description>
    <arm_group_label>All patient colonized with ESBL-E in Brest Intensive Care unit</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patient admitted in the ICU during a 5 years period (2015-2019) with a positive rectal&#xD;
        swab for ESBL-Enterobacteriae screening at the admission or during the ICU stay&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  admitted in Brest ICU (medical or surgical)&#xD;
&#xD;
          -  positive rectal swab for ESBL-Enterobacteriae screening at the admission or during the&#xD;
             ICU stay&#xD;
&#xD;
          -  written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  refusing to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre Bailly</last_name>
    <phone>0298347181</phone>
    <email>pierre.bailly@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe penven</last_name>
    <phone>0298347181</phone>
    <email>philippe.penven@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Pierre Bailly</last_name>
      <phone>0298347181</phone>
      <email>pierre.bailly@chu-brest.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available after the publication of result and ending five years maximum following the last visit of the last patient</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. requestors will be required to sign and complete a data access agreement</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

